Organizations helping pharmacists make transition to e-prescribing
BOSTON Several health worker organizations and the eHealth Initiative have released a how-to guide to help clinicians decide when and how to transition from paper to electronic prescribing systems, eHI announced at the Centers for Medicare and Medicaid Services National e-Prescribing Conference in Boston Tuesday.
The guide, “A Clinicians Guide to Electronic Prescribing,” is the result of collaboration efforts between eHI, the American Medical Association, the American Academy of Family Physicians, the American College of Physicians, the Medical Group Management Association and the Center for Improving Medication Management.
“We know e-prescribing is an efficient way to improve healthcare delivery, decrease medication errors and prevent potentially dangerous drug interactions,” eHI chief executive officer Janet Marchibroda said. “However, the transition from a paper to electronic system is quite challenging.”
The organizations developed the guide under the guidance of a steering group comprising clinicians, consumers, employers, health plans, pharmacies and four major medical associations.
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.